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Children, as opposed to adults, present with a vari-
ety of genetic nonmalignant disorders (NMD) that
have the potential for significant morbidity and prema-
ture mortality. These disorders include, but are not
limited to, hemoglobinopathies [1], bone marrow fail-
ure syndromes [2], inherited metabolic disorders [3],
and primary immunodeficiency disorders [4]. Alloge-
neic hematopoietic stem cell transplantation (HSCT)
has been shown to be curative for several of these dis-
orders—either by direct replacement of defective bone
marrow precursors as in hemoglobinopathies, primary
immunodeficiencies, and bone marrow failure syn-
dromes, or indirectly by delivering normal enzymes
to the affected tissues such as liver and brain, through
the medium of donor cells [5]. However, unlike hema-
tologic malignancies, patients with NMD generally
do not receive chemotherapy or immunosuppressive
therapy before HSCT and are appropriately regarded
as chemotherapy naive, thereby implying increased
resistance to engraftment compared to patients with
hematologic malignancies.Rationale for Reduced-Intensity Conditioning
(RIC) Transplantation in Pediatric NMD
Single, partially HLA-mismatched, unrelated donor,
umbilical cord blood transplantation (UCBT) is an im-
portant alternative donor source for patients lacking
a matched related or unrelated bone marrow or
peripheral blood stem cell (PBSC) donor.UCBT in con-DukeUniversity School ofMedicine, Pediatric Blood and
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6/j.bbmt.2011.10.013junction with myeloablative conditioning (MAC) has re-
sulted in the cure of hundreds of patients—children as
well as adults—with a variety ofmalignant andnonmalig-
nant diseases [6-8].However,myeloablative conditioning
is associated with significant short-term as well as long-
term morbidity and mortality. Outcomes described in
several large retrospective and prospective studies of sin-
gle UCBT and MAC indicate early treatment-related
mortality (TRM) ranging from 20% to 30% in the pedi-
atric population, and even higher in the adult population
[9-12]. In addition, the late effects of MAC, such as
growth failure, infertility, and second malignancies,
have a more profound impact on children who, upon
survival, have several decades of life ahead of them [13].
Therefore, approaches to decrease transplant-related
morbidity and mortality are clearly needed. Reducing
the intensity of pretransplantation conditioning is a logi-
cal approach to address this issue [14]. RIC often leads to
mixed chimerism. Although this can be problematic in
patients with malignancies (because of lack of cord blood
cells available for posttransplantation interventions such
as donor leukocyte infusion), there is evidence thatmixed
chimerismcan remain stable over time and result in a cure
in the case ofNMDwithout the need for additional inter-
ventions, thus providing a rational basis to expand this ap-
proach in NMD patients [15,16].
Several studies in recent years havedemonstrated ef-
ficacy and safety of the RIC approach in pediatric
patients with NMD [14]. The main principle behind
these RIC regimens is to use increased immunosuppres-
sion, thus enabling decreases in the intensity of myelo-
suppression and associated extra-medullary toxicities,
such as veno-occlusive disease, interstitial pneumonitis,
hemorrhagic cystitis, mucositis, etc. These regimens,
thus, are designed with a backbone of immunosuppres-
sive agents, fludarabine (Flu), and T cell–depleting
antibodies, suchas alemtuzumabor antithymycyteglob-
ulin (ATG) in combination with less than conventional
intensities of 1 or more alkylating agents (eg, busulfan
[Bu], melphalan [Mel], cyclophosphamide [Cy], thio-
tepa), and/or low-dose total body irridiation (TBI).
Spectrum of regimen intensity in published reports has
ranged from minimally intensive/nonmyeloablative
[17,18] to nearly ablative, but reduced toxicity [19-24].S53
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Regimens
Iannone et al. [17] described 7 patients with hemo-
globinopathies treated with a minimally intensive
nonmyeloablative regimen consisting of fludarabine
and TBI 200 cGy and HLA-identical related donors.
Although there was no TRM, none of the patients
had durable donor cell engraftment. Recently, how-
ever, Hsieh et al. [18] reported durable engraftment
in 9 of 10 adults with sickle cell disease undergoing
HLA-identical PBSC transplantations with a well-
tolerated nonmyeloablative regimen of alemtuzumab,
TBI 300 cGy, and sirolimus. At a median follow-up
of 30 months, most patients were continued on immu-
nosuppression with sirolimus. Future updates on the
extent of durability of donor chimerism after discontin-
uation of immunosuppression will be of great interest.
Reduced Intensity/Reduced Toxicity Regimens
Using the Flu/Bu8/ATG approach, where the Bu
dose was reduced to 8 mg/kg instead of the conven-
tional 16 mg/kg, Jacobson et al. [20] demonstrated
full donor chimerism in 72% of pediatric NMD pa-
tients, with the notable exception of hemoglobinopa-
thies, where 3 of 4 patients failed to achieve sustained
donor chimerism. Krishnamurti et al. [21] were able
to demonstrate durable engraftment in 7 patients with
sickle cell disease undergoing HLA-identical related
donor HSCT using Flu/Bu8/ATG 1 TBI 500 cGy.
Similarly, several groups have reported successful
engraftment, low TRM, and excellent survival in pedi-
atric NMD with a combination of alemtuzumab, Flu,
and Mel, mostly using bone marrow or PBSC grafts
[22-25]. Veys et al. [25] treated 113 children with
PID using predominantly Flu/Mel/alemtuzumab and
reported stable donor chimerism in 81% and long-
term survival in 82% of patients. Shenoy et al. [23] re-
ported similar results in a pediatric NMD cohort of 16
patients with alemtuzumab/Flu/Mel conditioning,
with a different or ‘‘distal’’ schedule of alemtuzumab,
given 3 weeks before transplantation rather than
within a week before transplantation.
RIC and UCBT in Pediatric NMD
Majority of the patients treated in the studies de-
scribed so far have received live donor rather than
UCB grafts. The role of UCBT in the setting of RIC
inpediatricNMDisunder active investigation. In a study
from Columbia University, 100 consecutive children
received RIC (Flu/Bu8/ATG, N 5 45; Flu/Bu16/
ATG, N 5 35; Flu/Cy/ATG, N 5 20). Indication for
transplantation was NMD in one-half of these patients.
UCB was the graft source in 51 patients. Although the
overall results were excellent with 100-day TRM of
\5%, consistent engraftment with UCB grafts was
a challenge. Graft failure was noted in 48.3% of chemo-therapy naive patients receiving UCBT as opposed to
0% in non-cord blood grafts [26]. Similar results were
noted in a multicenter study of unrelated donor HSCT
in sickle cell disease patients using the alemtuzumab/
Flu/Mel regimen. These emerging data highlight the in-
creased resistance to engraftment of cord blood grafts in
chemotherapy naive pediatric patients undergoing RIC.
A pilot studywas led byDukeUniversity for patients
with NMD undergoing single donor UCBT [27]. The
conditioning regimen consisted of alemtuzumab
3.2 mg/kg, fludarabine 150 mg/m2, melphalan 140 mg/
m2, thiotepa 200 mg/m2, and hydroxyurea. Graft-
versus-host-disease (GVHD) prophylaxis consisted of
tacrolimus and mycophenolate. Fifteen patients (14 at
Duke, 1 at All Children’s Hospital, St. Petersburg, FL),
several of them with pretransplantation comorbidities,
and 47% from ethnic minorities, were transplanted at
a median age of 2.6 years for metabolic disorders
(N5 8), primary immunodeficiency disorders (N 5 5),
and transfusion-dependent anemias (N5 2).Themajor-
ity of the patients received UCB grafts that were HLA
mismatched (4 of 6 in 6, 5 of 6 in 7 patients), contained
a median infused total nucleated cell dose of 7.8 
107/kg, and aCD341 dose of 3.6 105/kg.The regimen
was well tolerated with no serious organ toxicities attrib-
utable to the conditioning regimen. Twelve patients en-
grafted at a median of 19 days posttransplantation.
Platelet engraftment (.50K untransfused) was achieved
in all engrafted patients at amedian of 39 days. At the last
evaluation, whole blood donor chimerism in engrafted
patients ranged from 63% to .98%. Grade II acute
GVHD was seen in 2 patients. None of the patients
have had acute GVHD grades III-IV. Extensive chronic
GVHD of skin was noted in 1 patient. Viral infections
were common in the first 100 days. Five patients devel-
oped adenoviremia, which was associated with death
in 2 patients. One additional patient with mixed
chimerismdiedonday1170of an acutehemolytic trans-
fusion reaction. Three patients are off immunosuppres-
sion with age-appropriate immune profiles. With
a median follow-up of 1.2 years, the overall and event-
free survivals were 79% and 67%, respectively. This
data suggests that reduced toxicity regimens canbe effec-
tive and well tolerated in children with NMD undergo-
ing UCBT without increasing the risk of acute GVHD
or chronic GVHD. The increased immunosuppression
involved in such regimens, however, should prompt in-
creased surveillance for viral infections, especially cyto-
megalovirus and adenovirus. Longer follow-up and an
increased number of transplantations will be needed to
further validate these results.CONCLUSION
There is progress as evidenced so far in employing
less toxic and simultaneously effective RIC regimens.
Biol Blood Marrow Transplant 18:S53-S55, 2012 S55RIC in Children with NMD Undergoing UCBTMulticenter trials will test the applicability of these ap-
proaches. Undoubtedly, newer RIC regimens will
emerge over the next few years that will specifically tar-
get unique diseases or age groups. The recent addition
of new diagnoses into newborn screening panels e.g.
severe combined immunodeficiency, Krabbe disease,
and other leukodystrophies will facilitate early identifi-
cation of these patients for transplant prior to develop-
ment of significant comorbidities, thereby further
improving outcomes. There is a difference in host
resistance to engraftment between those with primary
immune defects compared with defects of metabolism
that do not impact the immune system, explaining the
need for biologically rational but diverse strategies.
Clearly, one size will not fit all.ACKNOWLEDGMENTS
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